Literature DB >> 20130072

Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study.

Rebecca M Reynolds1, Javier Labad, Mark W J Strachan, Anke Braun, F Gerry R Fowkes, Amanda J Lee, Brian M Frier, Jonathan R Seckl, Brian R Walker, Jackie F Price.   

Abstract

CONTEXT: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis may underlie the metabolic syndrome, but whether circulating cortisol levels predict cardiovascular end points is less clear. People with type 2 diabetes are at increased cardiovascular disease risk and thus are suitable to study associations of plasma cortisol with cardiovascular risk.
OBJECTIVE: We aimed to assess whether altered HPA axis activity was associated with features of the metabolic syndrome and ischemic heart disease in people with type 2 diabetes. DESIGN AND
SETTING: We conducted a cross-sectional cohort study in the general community, including 919 men and women aged 67.9 (4.2) yr with type 2 diabetes (the Edinburgh Type 2 Diabetes Study). INTERVENTION: We measured fasting morning plasma cortisol. MAIN OUTCOME MEASUREMENT: Associations between cortisol levels, features of the metabolic syndrome, obesity, and ischemic heart disease were determined.
RESULTS: Elevated plasma cortisol levels were associated with raised fasting glucose and total cholesterol levels (P < 0.001). These findings remained significant after adjustment for potential confounding factors (P < 0.001). Elevated cortisol levels were associated with prevalent ischemic heart disease (>800 vs. <600 nmol/liter; odds ratio, 1.58; P = 0.02). This association remained significant after adjustment for duration and control of diabetes and other cardiovascular risk factors (P = 0.03).
CONCLUSIONS: The previously described associations between HPA axis activation and features of the metabolic syndrome are present among people with type 2 diabetes. Elevated plasma cortisol is also associated with a greater prevalence of ischemic heart disease, independent of conventional risk factors. Understanding the role of cortisol in the pathogenesis of ischemic heart disease merits further exploration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130072      PMCID: PMC3971455          DOI: 10.1210/jc.2009-2112

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

1.  The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.

Authors:  G A ROSE
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

2.  Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.

Authors:  Hau Liu; Dena M Bravata; Josel Cabaccan; Hershel Raff; Elisabeth Ryzen
Journal:  Clin Endocrinol (Oxf)       Date:  2005-12       Impact factor: 3.478

3.  The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men.

Authors:  J Filipovský; P Ducimetiére; E Eschwége; J L Richard; G Rosselin; J R Claude
Journal:  J Hypertens       Date:  1996-02       Impact factor: 4.844

4.  Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study.

Authors:  George Davey Smith; Yoav Ben-Shlomo; Andrew Beswick; John Yarnell; Stafford Lightman; Peter Elwood
Journal:  Circulation       Date:  2005-07-11       Impact factor: 29.690

5.  Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.

Authors:  Deborah J Wake; Roland H Stimson; Garry D Tan; Natalie Z M Homer; Ruth Andrew; Fredrik Karpe; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2007-02-27       Impact factor: 5.958

6.  Plasma insulin, growth hormone, cortisol, and central obesity among young Chinese type 2 diabetic patients.

Authors:  Z S Lee; J C Chan; V T Yeung; C C Chow; M S Lau; G T Ko; J K Li; C S Cockram; J A Critchley
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

7.  The pituitary response to ovine corticotropin-releasing hormone is enhanced in obese men and correlates with insulin resistance.

Authors:  M P Solano; M Kumar; B Fernandez; L Jones; R B Goldberg
Journal:  Horm Metab Res       Date:  2001-01       Impact factor: 2.936

8.  Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes.

Authors:  Hannah Bruehl; Melanie Rueger; Isabel Dziobek; Victoria Sweat; Aziz Tirsi; Elizabeth Javier; Alyssa Arentoft; Oliver T Wolf; Antonio Convit
Journal:  J Clin Endocrinol Metab       Date:  2007-04-10       Impact factor: 5.958

9.  Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study.

Authors:  E J Brunner; H Hemingway; B R Walker; M Page; P Clarke; M Juneja; M J Shipley; M Kumari; R Andrew; J R Seckl; A Papadopoulos; S Checkley; A Rumley; G D O Lowe; S A Stansfeld; M G Marmot
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

10.  The Edinburgh Type 2 Diabetes Study: study protocol.

Authors:  Jackie F Price; Rebecca M Reynolds; Rory J Mitchell; Rachel M Williamson; F Gerald R Fowkes; Ian J Deary; Amanda J Lee; Brian M Frier; Peter C Hayes; Mark W J Strachan
Journal:  BMC Endocr Disord       Date:  2008-12-11       Impact factor: 2.763

View more
  36 in total

1.  Cortisol Measures Across the Weight Spectrum.

Authors:  Melanie Schorr; Elizabeth A Lawson; Laura E Dichtel; Anne Klibanski; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

Review 2.  Meditation and coronary heart disease: a review of the current clinical evidence.

Authors:  Indranill Basu Ray; Arthur R Menezes; Pavan Malur; Aimee E Hiltbold; John P Reilly; Carl J Lavie
Journal:  Ochsner J       Date:  2014

3.  Hyperactivity of the hypothalamic-pituitary-adrenal axis in patients with type 2 diabetes and relations with insulin resistance and chronic complications.

Authors:  Ivana Prpić-Križevac; Silvija Canecki-Varžić; Ines Bilić-Ćurčić
Journal:  Wien Klin Wochenschr       Date:  2012-06-26       Impact factor: 1.704

4.  Cortisol responses to emotional stress in men: association with a functional polymorphism in the 5HTR2C gene.

Authors:  Beverly H Brummett; Cynthia M Kuhn; Stephen H Boyle; Michael A Babyak; Ilene C Siegler; Redford B Williams
Journal:  Biol Psychol       Date:  2011-10-01       Impact factor: 3.251

Review 5.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

Review 6.  [Depression and diabetes mellitus type 2].

Authors:  M Deuschle; U Schweiger
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

7.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

8.  Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation(®) Program: A Research Review Update.

Authors:  Vernon A Barnes; David W Orme-Johnson
Journal:  Curr Hypertens Rev       Date:  2012-08

9.  Chronic variable stress improves glucose tolerance in rats with sucrose-induced prediabetes.

Authors:  Amy E B Packard; Sriparna Ghosal; James P Herman; Stephen C Woods; Yvonne M Ulrich-Lai
Journal:  Psychoneuroendocrinology       Date:  2014-05-29       Impact factor: 4.905

10.  Long-term glucocorticoid concentrations as a risk factor for childhood obesity and adverse body-fat distribution.

Authors:  G Noppe; E L T van den Akker; Y B de Rijke; J W Koper; V W Jaddoe; E F C van Rossum
Journal:  Int J Obes (Lond)       Date:  2016-06-24       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.